- Email: [email protected]
Correction to Lancet Oncol 2015; 16: 303
Corrections
Correction to Lancet Oncol Correction to Lancet Oncol Correction to Lancet Oncol 2016; 17: 65 2016; 17: e8 2015; 16: 303 Penson RT, Huang HQ, Wenzel LB, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology–Gynecologic Oncology Group protocol 240). Lancet Oncol 2015; 16: 301–11—In the ‘6 months post-cycle 1’ section of table 1 of this Article, in the ‘received’ row of the second column (headed cisplatin and paclitaxel plus bevacizumab), the data should have been 66 (57%). This correction has been made to the online version as of Dec 22, 2015.
www.thelancet.com/oncology Vol 17 January 2016
Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol 2016; 17: 57–66—In this Article, on page 65, paragraph 6, of the discussion section, reference 3 was incorrectly added to the sentence “Results of our published study8 in the first-line setting”. On page 65, in paragraph 8 of the discussion section, the approval date of rituximab by the EMA should have read “2006”. These corrections have been made to the online version as of Dec 22, 2015, and the the printed version is correct.
Baker H. Genetic mutations in paediatric cancer. Lancet Oncol 2016; 17: e8—In paragraph two of this News piece, the percentage of genetic mutations in paediatric should have read “95 (8·5%) of 1120 patients had genetic mutations in their normal tissue that increased their risk of developing cancer during childhood”. This correction has been made to the online version as of Dec 22, 2015.
e6
Correction to Lancet Oncol Correction to Lancet Oncol Correction to Lancet Oncol 2016; 17: 65 2016; 17: e8 2015; 16: 303 Penson RT, Huang HQ, Wenzel LB, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology–Gynecologic Oncology Group protocol 240). Lancet Oncol 2015; 16: 301–11—In the ‘6 months post-cycle 1’ section of table 1 of this Article, in the ‘received’ row of the second column (headed cisplatin and paclitaxel plus bevacizumab), the data should have been 66 (57%). This correction has been made to the online version as of Dec 22, 2015.
www.thelancet.com/oncology Vol 17 January 2016
Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol 2016; 17: 57–66—In this Article, on page 65, paragraph 6, of the discussion section, reference 3 was incorrectly added to the sentence “Results of our published study8 in the first-line setting”. On page 65, in paragraph 8 of the discussion section, the approval date of rituximab by the EMA should have read “2006”. These corrections have been made to the online version as of Dec 22, 2015, and the the printed version is correct.
Baker H. Genetic mutations in paediatric cancer. Lancet Oncol 2016; 17: e8—In paragraph two of this News piece, the percentage of genetic mutations in paediatric should have read “95 (8·5%) of 1120 patients had genetic mutations in their normal tissue that increased their risk of developing cancer during childhood”. This correction has been made to the online version as of Dec 22, 2015.
e6